Literature DB >> 17479256

ANP is cleared much faster than BNP in patients with congestive heart failure.

Kuniko Kimura1, Yukinari Yamaguchi, Manabu Horii, Hiroyuki Kawata, Hiromitsu Yamamoto, Shiro Uemura, Yoshihiko Saito.   

Abstract

OBJECTIVE: To obtain a better understanding of the pharmacokinetics of atrial and brain natriuretic peptides (ANP and BNP, respectively), two peptide mediators used in the treatment of congestive heart failure (CHF). Although both peptides exert their effects by binding to a common receptor (natriuretic peptide receptor A) with about the same affinity, their respective loading and maintenance doses differ.
METHODS: Sixteen CHF patients were randomized to be infused for 2 h with alpha-human ANP (0.05 microg/kg per minute) or BNP (0.01 microg/kg per minute). Plasma concentrations of both peptides were measured 0, 2, 5, 15, 30, 60 and 120 min post-infusion. The pharmacokinetic parameters were then calculated using a 1-compartment model.
RESULTS: The plasma BNP concentrations in the ANP and BNP groups before infusion were 464.7 +/- 339.8 and 506.8 +/- 332.5 pg/ml, respectively. Following infusion, ANP disappeared from the circulation more rapidly than BNP: their plasma half-lives were 2.4 +/- 0.7 and 12.1 +/- 3.0 min, and their total body clearance volumes were 48.2 +/- 24.1 and 10.1 +/- 2.7 ml/min per kilogram, respectively.
CONCLUSION: ANP has a shorter half-life in the plasma of CHF patients than BNP, which suggests that it controls hemodynamics more readily than BNP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479256     DOI: 10.1007/s00228-007-0309-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Systemic and renal effects of atrial natriuretic peptide in patients with heart failure treated with angiotensin-converting enzyme inhibitor or in acute saline solution loading.

Authors:  H Tomiyama; G Watanabe; M Abe; R Okazaki; H Yoshida; N Doba
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

Review 2.  Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides.

Authors:  K Nakao; Y Ogawa; S Suga; H Imura
Journal:  J Hypertens       Date:  1992-09       Impact factor: 4.844

3.  Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera.

Authors:  B D Bennett; G L Bennett; R V Vitangcol; J R Jewett; J Burnier; W Henzel; D G Lowe
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

4.  The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family.

Authors:  S Schulz; S Singh; R A Bellet; G Singh; D J Tubb; H Chin; D L Garbers
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

5.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.

Authors:  Jonathan D Sackner-Bernstein; Marcin Kowalski; Marshal Fox; Keith Aaronson
Journal:  JAMA       Date:  2005-04-20       Impact factor: 56.272

6.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Authors:  W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

7.  Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Takehiro Ishikawa; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  J Nucl Med       Date:  2004-07       Impact factor: 10.057

8.  Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man.

Authors:  T G Yandle; A M Richards; M G Nicholls; R Cuneo; E A Espiner; J H Livesey
Journal:  Life Sci       Date:  1986-05-19       Impact factor: 5.037

9.  Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men.

Authors:  P J Hunt; E A Espiner; A M Richards; T G Yandle; C Frampton; M G Nicholls
Journal:  Am J Physiol       Date:  1995-12

10.  Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor.

Authors:  J Okolicany; G A McEnroe; G Y Koh; J A Lewicki; T Maack
Journal:  Am J Physiol       Date:  1992-09
View more
  10 in total

Review 1.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

2.  Biomarker changes during acute heart failure treatment.

Authors:  Brent Boyer; Kimberly W Hart; Matthew I Sperling; Christopher J Lindsell; Sean P Collins
Journal:  Congest Heart Fail       Date:  2011-10-17

Review 3.  Corin: A Key Mediator in Sodium Homeostasis, Vascular Remodeling, and Heart Failure.

Authors:  Xianrui Zhang; Xiabing Gu; Yikai Zhang; Ningzheng Dong; Qingyu Wu
Journal:  Biology (Basel)       Date:  2022-05-07

4.  Cardiac complications of chemotherapy: role of biomarkers.

Authors:  Alessandro Colombo; Maria T Sandri; Michela Salvatici; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-06

Review 5.  Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.

Authors:  Erik H Howell; Scott J Cameron
Journal:  Cardiol J       Date:  2016-09-26       Impact factor: 2.737

6.  Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels.

Authors:  Hironobu Minami; Takanori Yasu; Tatsuya Tagawa; Ken Yamakawa; Shinichiro Ueda
Journal:  Eur J Clin Pharmacol       Date:  2008-07-12       Impact factor: 2.953

Review 7.  The use of biomarkers in the patient with heart failure.

Authors:  Punam Chowdhury; Devin Kehl; Rajiv Choudhary; Alan Maisel
Journal:  Curr Cardiol Rep       Date:  2013-06       Impact factor: 2.931

Review 8.  Molecular signatures of obstructive sleep apnea in adults: a review and perspective.

Authors:  Erna S Arnardottir; Miroslaw Mackiewicz; Thorarinn Gislason; Karen L Teff; Allan I Pack
Journal:  Sleep       Date:  2009-04       Impact factor: 5.849

Review 9.  Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases.

Authors:  Hitoshi Nakagawa; Yoshihiko Saito
Journal:  Biology (Basel)       Date:  2022-07-06

Review 10.  Natriuretic peptides in cardiovascular diseases.

Authors:  Mariusz Piechota; Maciej Banach; Anna Jacoń; Jacek Rysz
Journal:  Cell Mol Biol Lett       Date:  2008-04-10       Impact factor: 5.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.